Skip to content

Multi-center clinical study of sodium tanshinone IIA sulfonate on prognosis of patients with acute coronary syndrome

Multi-center clinical study of sodium tanshinone IIA sulfonate on prognosis of patients with acute coronary syndrome

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14005182
Enrollment
Unknown
Registered
2014-07-22
Start date
2014-09-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome

Interventions

Treatment:sodium tanshinone IIA sulfonate and standard thera
Control:standard therapy

Sponsors

2nd Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) with the diagnosis of acute coronary syndrome (including unstable angina and non ST elevation myocardial infarction); (2) TIMI score more than 3; (3) To be aged between 18 to 80 years old; (4) Plan to the coronary artery interventional therapy; (5) signed the informed consent.

Exclusion criteria

Exclusion criteria: The patient who complicated with any one of following conditions will be excluded: (1) patients with ST segment elevation myocardial infarction; (2) cardiogenic shock; (3) Severe heart failure (cardiac function class IV or left ventricular ejection fraction less than 30%); (4) severe blood system, nervous system diseases and malignant tumors; (5) the serious impairment of liver and renal function (serum ALT higher than normal amount of the upper limit value of the three times and / or serum creatinine higher than 265umol/L); (6) active bleeding; (7) pregnant women, lactation and planning of women patients; (8) patients participate in other study.

Design outcomes

Primary

MeasureTime frame
incidence of major adverse cardiac event;

Secondary

MeasureTime frame
the incidence of composite key event;the level of CRP;contrast-induced nephropathy;the level of hemorrhage;

Countries

China

Contacts

Public ContactMinzhou Zhang
MinzhouZhang@gmail.com+86 13924266368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026